Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 20, 2024

Study Completion Date

February 20, 2024

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DEVICE

abdominal U/S

A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.

DEVICE

Fibroscan with Controlled Attenuated Parameter (CAP scan):

"Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m)."

Trial Locations (1)

44511

Zagazig University, Zagazig

All Listed Sponsors
collaborator

Suez University

OTHER

collaborator

Benha University

OTHER

lead

Zagazig University

OTHER_GOV